JBIO vs TRAX
JBIO: Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA nephropathy and rheumatoid arthritis. TRAX: Clinical-stage antibody-focused biotech advancing immune-modulating therapies for autoimmune and inflammatory diseases including celiac disease, eosinophilic esophagitis, and rheumatoid arthritis.
Side-by-side fundamentals
| Metric | JBIO | TRAX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.85 | $38.17 | |
| Market cap as of 2026-07-23 | $1.2B | $1.3B | |
| ROE as of 2026-07-23 | -51.3% | -57.8% | JBIO higher |
| ROA as of 2026-07-23 | -47.3% | -50.2% | JBIO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 1.42 | 1.19 | |
| 1-year return as of 2026-07-22 close | +136.2% | +100.9% | JBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.